Browsing Tag
ABTECT 1
2 posts
Abivax (NASDAQ: ABVX) obefazimod NDA path meets a safety debate the market is still pricing
Abivax (NASDAQ: ABVX) put up Rinvoq-like ulcerative colitis remission data and dropped 40 percent. The question is whether the malignancy debate sticks.
Abivax delivers breakthrough Phase 3 data: obefazimod improves quality of life in moderate-to-severe ulcerative colitis
Discover how Abivax’s obefazimod improved quality of life and achieved remission in Phase 3 ulcerative colitis trials—see why experts call it a game changer.